GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Scilex Holding Co (NAS:SCLX) » Definitions » YoY EBITDA Growth

Scilex Holding Co (Scilex Holding Co) YoY EBITDA Growth : -29.65% (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Scilex Holding Co YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Scilex Holding Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -29.65%.

Scilex Holding Co's EBITDA per Share for the three months ended in Mar. 2024 was $-0.22.


Scilex Holding Co YoY EBITDA Growth Historical Data

The historical data trend for Scilex Holding Co's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scilex Holding Co YoY EBITDA Growth Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
- 80.54 -45.89 78.34 -1,046.58

Scilex Holding Co Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -191.53 -81.82 -232.79 -77.39 -29.65

Scilex Holding Co YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Scilex Holding Co's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.837--0.073)/ | -0.073 |
=-1,046.58 %

Scilex Holding Co's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.223--0.172)/ | -0.172 |
=-29.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scilex Holding Co YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Scilex Holding Co's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


Scilex Holding Co (Scilex Holding Co) Business Description

Traded in Other Exchanges
N/A
Address
960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is engaged in the development and commercialization of non-opioid pain management products. The company's lead product ZTlido.
Executives
Sclx Stock Acquisition Jv Llc 10 percent owner 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Jay Chun director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Stephen Hoi Ma officer: Chief Financial Officer C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Tien-li Lee director C/O SCILEX HOLDING COMPANY, 960 SAN ANTONIO ROAD, PALO ALTO CA 94303
Sorrento Therapeutics, Inc. 10 percent owner 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
David Lemus director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Dorman Followwill director C/O SORRENTO THERAPEUTICS, INC., 4955 DIRECTOR'S PLACE, SAN DIEGO CA 92121
Henry Ji director, officer: Executive Chairperson 5370 RUETTE DE MER, SAN DIEGO CA 92130
Jaisim Shah director, officer: See Remarks C/O PROTINE DESIGN LAB, 37481 MARSTEN DR, NEWARK CA 94560
Elizabeth Czerepak officer: See Remarks 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Laura Hamill director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Suneel G Kaji director 25/28 OLD BURLINGTON STREET, LONDON X0 W1S 3AN
Steve Myint director C/O VICKERS VANTAGE CORP. I, 1 HARBOURFRONT AVENUE, #16-06, SINGAPORE U0 098632

Scilex Holding Co (Scilex Holding Co) Headlines

From GuruFocus